SCHEMBL4784703

SCHEMBL4784703

Nc1ccc2[nH]nc(-c3ncco3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 3/20 0.48
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
LRRK2 Q5S007 3/20 0.43
GSK3B P49841 1/20 0.42
AURKA O14965 1/20 0.41
TTBK1 Q5TCY1 1/20 0.39
PIKFYVE Q9Y2I7 1/20 0.39
JAK2 O60674 2/20 0.36
PDPK1 O15530 1/20 0.36
CLK2 P49760 3/20 0.36
DYRK1A Q13627 3/20 0.36
CLK3 P49761 2/20 0.36
DCLK1 O15075 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
CHEK2 O96017 1/20 0.36
CSF1R P07333 1/20 0.36
FER P16591 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4452729 0.80 LRRK2 (0.54) HTR2AHTR2CHTR2BLRRK2AURKA
SCHEMBL4783909 0.76 MAPT (0.61) LRRK2CDK2
SCHEMBL1663211 0.75 AXL (0.60) AXLHTR2AHTR2CHTR2BGSK3B
SCHEMBL2473158 0.74 AXL (0.52) AXLHTR2AHTR2CHTR2BLRRK2
SCHEMBL22445971 0.74 NTRK1 (0.56) AXLHTR2AHTR2CHTR2BLRRK2
SCHEMBL29643873 0.74 NTRK1 (0.56) AXLHTR2AHTR2CHTR2BLRRK2
SCHEMBL4222590 0.73 AXL (0.55) AXLHTR2AHTR2CHTR2BLRRK2
SCHEMBL12193658 0.72 MKNK1 (0.61) AXLHTR2AHTR2CHTR2BLRRK2
SCHEMBL4008208 0.72 DCLK1 (0.65) AXLHTR2AHTR2CHTR2BLRRK2
SCHEMBL31423230 0.72 DCLK1 (0.65) AXLHTR2AHTR2CHTR2BLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020191261-A1 INDAZOLES AS LRRK2 INHIBITORS E-SCAPE BIO, INC. (US) 2020-09-24 WO disclosed
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
WO-2008061109-A2 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed
WO-2008061109-A2 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS MCHR1, MCHR2, MC1R AXL 1060/4885HTR2A 191/4885HTR2C 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.